|
EP2345731B1
(en)
*
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
WO2012109570A1
(en)
*
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
TR201908020T4
(tr)
|
2011-02-17 |
2019-06-21 |
Univ Pennsylvania |
Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
|
|
EP3318635A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
WO2013170078A1
(en)
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US20140219964A1
(en)
*
|
2013-02-07 |
2014-08-07 |
Children's Medical Center Corporation |
Methods for inducing cardiomyocyte proliferation
|
|
CA2905952A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
AU2014235096B2
(en)
|
2013-03-15 |
2020-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating MPSI
|
|
ES2926774T3
(es)
*
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
PL3628334T3
(pl)
|
2014-03-21 |
2023-12-18 |
Genzyme Corporation |
Terapia genowa w retinopatii barwnikowej
|
|
WO2015164757A1
(en)
*
|
2014-04-25 |
2015-10-29 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
PL4012035T3
(pl)
|
2014-09-16 |
2025-03-24 |
Genzyme Corporation |
Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
|
|
EP4012035B1
(en)
|
2014-09-16 |
2024-11-06 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
EA201791630A1
(ru)
|
2015-01-20 |
2018-04-30 |
Джензим Корпорейшн |
Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
|
|
CR20170406A
(es)
|
2015-02-10 |
2017-11-14 |
Genzyme Corp |
Arni variante
|
|
CN107530447A
(zh)
|
2015-02-10 |
2018-01-02 |
建新公司 |
病毒颗粒至纹状体和皮质的增强递送
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
BR112017024514A2
(pt)
|
2015-05-16 |
2018-07-24 |
Genzyme Corporation |
edição genética de mutações intrônicas profundas
|
|
WO2017019876A1
(en)
*
|
2015-07-28 |
2017-02-02 |
University Of Massachusetts |
Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
MX2018007330A
(es)
|
2015-12-15 |
2019-03-14 |
Genzyme Corp |
Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii.
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012195A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
SG10201912761UA
(en)
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CN106093369B
(zh)
*
|
2016-06-29 |
2017-10-20 |
福建农林大学 |
Bt水稻对非靶标害虫褐飞虱的安全性评价方法
|
|
CA3033856A1
(en)
|
2016-08-15 |
2018-02-22 |
Genzyme Corporation |
Methods for detecting aav
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
WO2018119330A2
(en)
*
|
2016-12-22 |
2018-06-28 |
Oregon Health & Science University |
Adeno associated viral vectors
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
CN111356763B
(zh)
|
2017-09-22 |
2024-03-12 |
建新公司 |
变体RNAi
|
|
KR102883778B1
(ko)
|
2017-09-22 |
2025-11-12 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
KR20230065367A
(ko)
*
|
2018-02-01 |
2023-05-11 |
호몰로지 메디슨, 인크. |
Pah 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
MA51353B1
(fr)
|
2018-04-05 |
2022-09-30 |
Univ Sorbonne |
Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
|
|
US12460226B2
(en)
|
2018-04-16 |
2025-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
WO2019213668A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Oregon Health & Science University |
Human anti-aav2 capsid polyclonal antibody epitopes
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
CN112770812A
(zh)
|
2018-07-24 |
2021-05-07 |
沃雅戈治疗公司 |
产生基因治疗制剂的系统和方法
|
|
KR102931619B1
(ko)
|
2018-08-03 |
2026-02-26 |
젠자임 코포레이션 |
알파-시뉴클레인에 대한 변이형 RNAi
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
AU2019357039B2
(en)
|
2018-10-12 |
2025-10-09 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe PKU by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
WO2020160508A1
(en)
*
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220047618A1
(en)
|
2019-02-28 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
JP2022528010A
(ja)
*
|
2019-04-12 |
2022-06-07 |
ユニバーシティ オブ マサチューセッツ |
メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療
|
|
US20220233655A1
(en)
*
|
2019-05-17 |
2022-07-28 |
Research Institute At Nationwide Children's Hospital |
Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
JP2022551739A
(ja)
*
|
2019-10-17 |
2022-12-13 |
ストライドバイオ，インコーポレイテッド |
ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
|
|
WO2021087361A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
US12064894B2
(en)
|
2020-09-04 |
2024-08-20 |
Milwaukee Electric Tool Corporation |
Chainsaw
|
|
MX2023003805A
(es)
|
2020-10-01 |
2023-04-12 |
Genzyme Corp |
Casete de expresion de pah humana para el tratamiento de la pku mediante terapia de reemplazo genico dirigida al higado.
|
|
WO2022165313A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
CN119317718A
(zh)
*
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
CN121586778A
(zh)
|
2023-04-26 |
2026-02-27 |
赛诺菲 |
宿主细胞系以及用于鉴定和使用此类宿主细胞系的方法
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|
|
WO2026030242A1
(en)
|
2024-07-29 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
|
|
WO2026030244A1
(en)
|
2024-07-30 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
|
|
WO2026050402A1
(en)
|
2024-08-29 |
2026-03-05 |
Kate Therapeutics, Inc. |
Liver de-targeted muscle tropic capsids
|